ClinicalTrials.gov
ClinicalTrials.gov Menu

C-Reactive Protein and Endothelial Dysfunction in Women With Glucose Intolerance

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT00589355
Recruitment Status : Unknown
Verified December 2007 by Yale University.
Recruitment status was:  Active, not recruiting
First Posted : January 9, 2008
Last Update Posted : January 9, 2008
Sponsor:
Information provided by:
Yale University

December 27, 2007
January 9, 2008
January 9, 2008
January 2002
June 2003   (Final data collection date for primary outcome measure)
c-reactive protein [ Time Frame: performed after screening evaluation ]
Same as current
No Changes Posted
  • flow-mediated dilation of brachial artery [ Time Frame: performed twice after screening visit ]
  • sex steroids [ Time Frame: performed after screening visit ]
Same as current
Not Provided
Not Provided
 
C-Reactive Protein and Endothelial Dysfunction in Women With Glucose Intolerance
C-Reactive Protein and Endothelial Dysfunction in Women With Glucose Intolerance
The goal of this study is to determine whether markers of vascular inflammation (such as c-reactive protein) can predict endothelial dysfunction (as measured by flow-mediated dilation) in postmenopausal women with glucose intolerance compared to normal controls.
Not Provided
Observational
Observational Model: Case Control
Time Perspective: Cross-Sectional
Not Provided
Not Provided
Non-Probability Sample
Two groups of healthy postmenopausal women who do not smoke. One group includes women with either pre-diabetes or diet-controlled diabetes. The control group includes women with normal glucose tolerance
Glucose Intolerance
Not Provided
  • 1
    postmenopausal women with glucose intolerance (either pre-diabetes or diet-controlled diabetes)
  • 2
    postmenopausal women with normal glucose tolerance
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Unknown status
46
Same as current
October 2008
June 2003   (Final data collection date for primary outcome measure)

Inclusion Criteria:

  • healthy postmenopausal women
  • ages 40-65

Exclusion Criteria:

  • smokers
  • diabetes requiring medication
Sexes Eligible for Study: Female
40 Years to 65 Years   (Adult)
Yes
Contact information is only displayed when the study is recruiting subjects
United States
 
 
NCT00589355
12110
No
Not Provided
Not Provided
Barbara I Gulanski, MD, MPH, Yale University School of Medicine
Yale University
Not Provided
Principal Investigator: Barbara I Gulanski, MD, MPH Yale University
Yale University
December 2007